MorphoSys (ETR:MOR) has been assigned a €107.00 ($124.42) target price by investment analysts at Commerzbank in a note issued to investors on Friday, November 16th. The brokerage currently has a “neutral” rating on the stock. Commerzbank’s price objective indicates a potential upside of 3.18% from the stock’s previous close.
A number of other brokerages have also commented on MOR. JPMorgan Chase & Co. set a €100.00 ($116.28) price target on MorphoSys and gave the stock a “buy” rating in a report on Thursday, July 19th. Oddo Bhf set a €110.00 ($127.91) target price on MorphoSys and gave the company a “buy” rating in a research note on Thursday, July 19th. Royal Bank of Canada set a €62.00 ($72.09) target price on MorphoSys and gave the company a “sell” rating in a research note on Thursday, July 19th. Independent Research set a €120.00 ($139.53) target price on MorphoSys and gave the company a “neutral” rating in a research note on Tuesday, August 7th. Finally, Berenberg Bank set a €108.00 ($125.58) price target on MorphoSys and gave the company a “neutral” rating in a research report on Friday, September 7th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of €97.30 ($113.14).
MorphoSys stock traded up €2.80 ($3.26) during mid-day trading on Friday, reaching €103.70 ($120.58). The stock had a trading volume of 154,810 shares, compared to its average volume of 153,687. MorphoSys has a fifty-two week low of €49.63 ($57.71) and a fifty-two week high of €88.10 ($102.44).
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Featured Story: How Short Selling Works
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.